Asymptomatic SARS coronavirus 2 infection: Invisible yet invincible-Reply to Malagon-Rojas et al

被引：0
|
作者：
Velavan, Thirumalaisamy P. [1 ,2 ,3 ]
Meyer, Christian G. [1 ,2 ,3 ]
机构：
[1] Univ Klinikum Tubingen, Inst Trop Med, Wilhelmstr 27, D-72074 Tubingen, Germany
[2] Vietnamese German Ctr Med Res VG CARE, Hanoi, Vietnam
[3] Duy Tan Univ, Fac Med, Da Nang, Vietnam
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 102卷
关键词：
D O I：
10.1016/j.ijid.2020.10.034
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 11 条
  • [1] Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible
    Nikolai, Lea A.
    Meyer, Christian G.
    Kremsner, Peter G.
    Velavan, Thirumalaisamy P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 100 : 112 - 116
  • [2] Letter to the editor on "Asymptomatic infection by SARS 2 coronavirus: Invisible but invincible" by Nikolai et al. 2020
    Malagon-Rojas, Jeadran
    Parra, Eliana
    Mercado, Marcela
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 391 - 392
  • [3] Reply to Radermacher et al. on "Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus"
    Renieris, Georgios
    Katrini, Konstantina
    Giamarellos-Bourboulis, Evangelos J.
    SHOCK, 2021, 55 (01): : 139 - 140
  • [4] Reply to Fillmore et al.: Additional evidence of non-SARS-CoV-2 coronavirus cross-immunity
    Solomon, Matthew D.
    Steinman, Lawrence
    Liu, Vincent X.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (46)
  • [5] Letter to the Editor concerning A study on infectivity of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) carriers by Gao et al
    Silverman, Erin P.
    Reddy, Raju
    Ataya, Ali
    Eagan, Christina
    RESPIRATORY MEDICINE, 2022, 191
  • [6] Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
    Eric J. Lenze
    Angela M. Reiersen
    Shelley N. Facente
    Drugs, 2022, 82 : 353 - 354
  • [7] Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence"
    Lenze, Eric J.
    Reiersen, Angela M.
    Facente, Shelley N.
    DRUGS, 2022, 82 (03) : 353 - 354
  • [8] Reply to Comment on the article titled 'Nosocomial SARS-CoV-2 transmission in postoperative infection and mortality: analysis of 14,798 procedures' by Elliott JA et al.
    Elliott, Jessie A.
    Ridgway, Paul F.
    BRITISH JOURNAL OF SURGERY, 2021, 108 (01) : E54 - E54
  • [9] Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556"
    Favresse, Julien
    Gillot, Constant
    Douxfils, Jonathan
    MICROORGANISMS, 2021, 9 (09)
  • [10] Reply to Peng He, Xiaohui Wang, and Hao Li's Letter to the Editor re: Yu Xiao, Kaiyu Qian, Yongwen Luo, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol 2020;78:298-9
    Xiao, Yu
    Qian, Kaiyu
    Luo, Yongwen
    Chen, Song
    Lu, Mengxin
    Wang, Gang
    Ju, Lingao
    Wang, Xinghuan
    EUROPEAN UROLOGY, 2020, 78 (05) : E203 - E204
12